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Bright Renoprotective Properties of Metformin 
Beyond Blood Glucose Regulatory Effects
Hamid Nasri,1 Azar Baradaran,2 Mohammad Reza Ardalan,3  
Saeed Mardani,4 Ali Momeni,4 Mahmoud Rafieian-Kopaei4
Metformin, a biguanide drug, is widely prescribed to treat high 
blood glucose in individuals with type 2 diabetes mellitus. Type 
2 diabetes mellitus is a troubling chronic disease and diabetic 
nephropathy is one of the most important complications of diabetes 
mellitus. Recent studies suggest that metformin, in addition to 
its efficacy in treating type 2 diabetes, may also have therapeutic 
efficacy in other conditions, including diabetic nephropathy 
or ameliorative property against tubular cell injury. Moreover, 
metformin significantly decreases albuminuria in patients with 
type 2 diabetes mellitus. However, the exact mechanisms beyond 
the effect of metformin on blood glucose are still unknown. Recent 
studies suggest that the therapeutic effect of metformin is mediated 
by its action on adenosine monophosphate-activated protein 
kinase in tissues. Various investigations show that metformin 
decreases intracellular reactive oxygen species. Metformin protects 
against tubular injury by restoring the biochemical alterations and 
regulation of oxidative stress on renal tubules. It also protects 
podocytes in nephropathy of diabetes. These findings can more 
strongly potentiate the clinical use of metformin in the prevention 
of nephropathy of diabetes. In this regard, to better understand 
the metformin nephroprotective properties, more experimental rat 
models and clinical studies are needed.
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INTRODUCTION
Metformin, an oral antidiabetic drug in the 
biguanide class is a widely prescribed drug to 
treat high blood glucose in individuals with 
type 2 diabetes mellitus (DM).1,2 Despite clinical 
introduction in the 1950s, the exact mechanism 
action of metformin is not yet fully understood. 
Indeed, considerable research has been made from 
many years ago to better discover the molecular 
and cellular mechanisms of action of metformin.2,3 
The antihyperglycemic properties of metformin 
are mainly attributed to the suppression of liver 
glucose production and increase in peripheral 
tissue insulin sensitivity.4 This drug improves 
insulin sensitivity without decreasing the glucose 
concentration below normal values.4 Metformin has 
90% to 100% renal excretion as unchanged drug, 
and its clearance is reduced in kidney dysfunction. 
Metformin plasma half-life is 1.5 to 4.9 hours 
in healthy persons.5 Metformin has high water 
solubility, negligible protein binding in serum, 
and a large volume of distribution, because it 
diffuses freely into the intracellular compartment 
and binds to microsomes.4,5 By a mild and transient 
inhibition of respiratory-chain complex 1 in 
the mitochondria, metformin can decrease liver 
glucose production.6-9 Moreover, the decrease in 
hepatic energy status, leads activation of adenosine 
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monophosphate-activated protein kinase (AMPK), 
which may explain the mechanism of metformin 
action on liver gluconeogenic process.10 
In addition to its effect on blood glucose, 
metformin was also reported to have beneficial 
effects on microvascular and macrovascular 
complications associated with type 2 DM.11 
Furthermore, metformin is beneficial in gestational 
DM, for the prevention in prediabetic persons.12-14 In 
addition, by increasing sensitization to insulin and 
resultant reduction in insulin resistance, reduction 
in plasma fasting insulin level was also found with 
metformin, too. The improvement of sensitivity 
to insulin by metformin could be attributed to its 
positive effects on insulin receptor expression and 
tyrosine kinase activity.12-15 Recent findings have 
established that metformin possesses antioxidant 
properties, too.11,16,17 Reduction of apoptosis, 
induced by oxidative stress, in endothelial cells 
and prevention of vascular dysfunction were also 
found with metformin treatment. In this review, 
the renal tubular protective efficacy of metformin 
and its protective efficiency in diabetic kidney 
disease are discussed.
MECHANISM OF ACTION
As mentioned above, the activation of AMPK 
was intimately associated with the pleiotropic 
actions of metformin,18 and this enzyme regulates 
cellular and organ metabolism.17-20 The AMPK is 
a phylogenetically conserved serine/threonine 
protein kinase envisaged as a fuel gauge monitoring 
systemic and cellular energy condition,18,19 and plays 
an important role in protecting cellular functions 
under energy-restricted conditions.20 Ample 
evidence attests that AMPK activation by metformin 
is secondary to its effect on the mitochondria as 
the primary target of this agent.19,20 Recent findings 
mentioned to the direct or mediated mitochondrial 
effect of metformin.21 Indeed, there is evidence 
that when it is used alone, the beneficial effect 
of metformin may be due to its mild inhibition 
of the mitochondrial respiratory chain (mainly 
of complex I).21-23 Various findings imply that 
metformin has ameliorative properties against toxic 
effects to the renal tubules.22-26 Among functions 
of mitochondria, their role in cell death and life 
decisions has gained special importance.25,26 While 
the crucial role of mitochondria in cell death is of 
significance, protecting mitochondria has become 
a prosurvival cell strategy.24-26 In this regard, the 
role of mitochondria in programmed cell death is 
associated with the release of apoptotic signaling 
molecules.11,25-31 Moreover, reactive oxygen species 
(ROS) production by mitochondria may also lead 
significantly to any cell degradation process.24,27-29 
The mechanism of mitochondrial ROS production 
in cells is not fully understood, because most of 
studies revealing ROS production were made in 
model systems.28,30 It was found that mitochondria 
represents one of the major cellular sources of 
ROS generation,28-30 and a great number of tissue 
pathologies, both inherited and acquired, were 
found to be associated with oxidative stress.30,31 
These f indings showed the cr i t ical  role  of 
mitochondria in these conditions.31,32 Previously, 
Morales and colleagues observed that gentamicin-
induced renal tubular damage is attenuated by 
metformin.33 Reactive oxygen species play a key 
role in the toxicity of gentamicin, resulting in acute 
kidney failure,34-36 and gentamicin is a mitochondrial 
toxin that can imply its toxic effects when excreted 
by the kidney.37-39 Mitochondrial toxicity can 
also be mediated by reactive oxygen species.24,32 
Reactive oxygen species are normally produced 
at low levels by mitochondria; however, under 
pathological conditions the intracellular and intra 
mitochondrial ROS content may be increased.22-24 
Indeed, in certain conditions, intracellular ROS 
content can reach a toxic level, which results in 
oxidative damage to the mitochondria, causing 
cell death and malfunctioning of the organ.22-24 
To test the potential properties of metformin to 
protect the kidney from gentamicin-induced acute 
kidney failure and also finding out that whether 
postpone treatment with metformin in acute 
kidney failure exerts similar benefits on gentamicin 
nephrotoxicity in rats, we conducted a study on 
male Wistar rats.40 We found out that metformin 
prevented and also ameliorated gentamicin-
induced acute kidney failure, and hence, it might 
be beneficial in patients under treatment with this 
drug.40 Recently, we also tested the efficacy of 
co-administration of garlic extract and metformin 
for prevention of gentamicin-renal tubular damage 
in 70 male Wistar rats. The result of this study 
demonstrates that metformin and garlic juice or their 
combination has both curative and protective effects 
against gentamicin nephrotoxicity.41 Accordingly, 
Taheri and coworkers recently conducted a study 
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on the effects of metformin on renal function and 
structure after unilateral ischemia-reperfusion in 
rats. They found that metformin provided some 
renal protection against ischemia and reperfusion 
induced damage to the rats’ kidney.42 Likewise, they 
also concluded that metformin with activation of 
AMPK and endothelial nitric oxide synthase have 
tissue protective effects.40 Thus, these data lend 
further evidence for the attribution of metformin 
in its renoprotective property in addition to its 
well-known hypoglycemic action. 
METFORMIN AND NEPHROPATHY
Diabetes mellitus is constituted of a group of 
metabolic diseases characterized by hyperglycemia 
resulting from defects in insulin secretion or 
action,43-45 and diabetes is nephropathy is one 
of the most important complications of DM.46 
Recently, much attention has also been directed 
towards the possible protective ameliorative role 
of metformin in diabetic kidney disease, too. 
Hyperglycemia amplifies oxidative stress and 
generation of ROS, which have a crucial role in 
the pathogenesis of diabetic nephropathy.47,48 In 
the study conducted by Alhaider and colleagues 
the effect of metformin on the biochemical changes 
associated with hyperglycemia was investigated in 
rat kidney tissues.49 In addition, they also assessed 
energy nucleotides (adenosine monophosphate and 
adenosine triphosphate), and acetyl-CoA in the 
renal homogenates and mitochondria and also pro-
inflammatory mediators. They found that treatment 
of normoglycemic rats with metformin caused 
significant increase in adenosine triphosphate and 
acetyl-CoA, contents in kidney homogenates and 
mitochondria along with profound decrease in 
adenosine monophosphate level. Also, treatment 
of nephropathy of DM in rats with metformin 
normalized all biochemical changes and the energy 
status in kidney tissues. At the transcriptional levels, 
metformin treatment caused significant restoration 
in diabetic nephropathy-induced oxidative stress 
mRNA levels.49 
Evidence suggests that ROS overproduction may 
be the key starting event that results to the long-
term development of complications of diabetes.50-52 
However, the specific mechanisms that link 
hyperglycemia with oxidative stress and diabetic 
nephropathy are poorly found.49,51,53 In general, 
nucleic acids can affected by oxidative stress and 
generate various modified bases in DNA. When 
DNA is damaged, affected cells start a response, 
such as DNA repair, cell cycle delay or apoptosis 
induction. The ROS generation by oxidative stress 
causes cell death.54-56 Apoptosis has been implicated 
in the pathogenesis of nephropathy of diabetes and 
reactive oxygen species is an inducer of apoptosis 
in various cell types including podocytes.54-58 
More recently, Kim and colleagues conducted a 
study using metformin for diabetic rats. They 
observed restoration of podocytes by metformin 
treatment in diabetic rats. They suggested that 
diabetes-induced podocyte loss in nephropathy 
of diabetes could be attenuated by metformin, 
by the repression of oxidative injury.59 They also 
showed that the density of podocytes decreases in 
diabetic rats in association with increased albumin 
excretion. Podocyte apoptosis has been detected to 
associate with increasing albuminuria. Moreover, 
there was evidence for the role of intracellular 
ROS as potent inducers of podocyte apoptosis, 
too.59 Therefore, metformin acts as an activator of 
AMPK, a major cellular regulator of glucose and 
lipid metabolism, and as an inhibitor of complex I 
of the respiratory chain in the mitochondria. Kim 
and colleagues found that the phosphorylation 
of AMPK was reduced in the kidney of diabetic 
rats, and metformin could restore its alteration. 
Therefore, metformin may exert some of its effects 
by improvement of renal oxidative stress. They 
suggested a potential clinical use of metformin 
in the prevention of diabetic kidney disease by 
inhibition of advanced glycation end products 
and free radical defense system improving.59 
These findings are in agreement with the study 
conducted by Liu and colleagues. They pointed 
the beneficial antioxidant properties of metformin 
in diabetic rats too.60 
It is well known that the injury of podocyte 
leads to the occurrence of proteinuria; therefore, 
the loss of glomerular podocytes precedes and 
predicts the onset of nephropathy and may be 
an early pathological manifestation of diabetic 
nephropathy. Metformin significantly decreased 
albuminuria in patients with type 2 DM.61 Previous 
studies have also shown the beneficial effects 
of metformin on reduction of macrovascular 
morbidity and mortality, suggesting that it implies 
antiatherogenic, antioxidant, and anti-inflammatory 
effects.59,61-63 Moreover, metformin significantly 
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decreased albuminuria in patients with type 2 
DM.59,61-63 The benefits of metformin using with its 
cardiovascular and metabolic parameters benefits 
suggest its clinical use in treating chronic kidney 
disease, too.1,7 The glomeruli have been at the focus 
of attention as the primary site of damage in diabetic 
kidney disease; however, it is also well known 
that tubulointerstitial changes are a prominent 
constituent of the disease, especially in patients with 
type 2 DM.64-66 The level of albuminuria and diabetic 
kidney disease progression best correlate with 
tubular degeneration and interstitial fibrosis.64-66 
In fact urinary biomarker data in human beings 
provide the view that proximal tubule damage 
contributes in a primary way, rather than in a 
secondary fashion, to the development of early 
diabetic kidney disease.66,67 Indeed, in the process 
of diabetic nephropathy, capillary rarefaction 
leads to local ischemia with further injury to the 
tubules, more profibrogenic mediators, matrix 
protein deposition, fibrosis, and aggravating the 
glomerulosclerosis.64-68 Hence, in diabetic kidney 
disease, the tubules show alterations that are usually 
associated with glomerular alterations, tubular 
cell degeneration, tubular apoptosis, and tubular 
atrophy.64-68 Therefore, it is reasonable to imply 
that metformin has 2 different roles: first, renal 
tubular cell protection, by acting as an effective 
antioxidant, and second, its ameliorative effect 
on diabetic kidney disease. However, diabetic 
patients may benefit from both of these two 
distinct properties, as well as its blood glucose 
regulatory effects.
CONCLUSIONS
Type 2 DM is a troubling chronic disease. 
Regarding the huge number of new cases diagnosed 
annually in the world, and diabetic nephropathy 
is one of the most important complications of DM. 
Recent studies suggest that metformin, in addition 
to its efficacy in treating type 2 DM, may also have 
therapeutic potential in other conditions including 
diabetic nephropathy. It may also be beneficial as 
an ameliorative agent against tubular cell injury. 
Moreover, metformin significantly decreases the 
urine albumin excretion rate in patients with type 
2 DM. However, the exact mechanisms beyond 
the effect of metformin are still are unknown. 
Recent studies suggest that therapeutic effect of 
metformin is mediated by its action on AMPK in 
tissues. Various investigations show that metformin 
decreases intracellular ROS. Metformin protects 
tubular injury by restoring the biochemical 
alterations and regulation of oxidative stress on 
renal tubules. Metformin also protects podocytes 
in diabetic nephropathy. 
These findings can potentiate the clinical use of 
metformin in the prevention of nephropathy of DM. 
In this regard, to better understand the metformin 
nephroprotective properties, more preclinical and 
clinical studies are suggested.
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